Replies to post #250974 on Biotech Values

[DewDiligence]

LEXX has a curious sequence of announcements vis-à-vis GLP-1. In Nov 2023, LEXX issued a PR with some scant data on pairing LEXX’s drug-delivery technology with NVO’s Rybelsus:

https://ir.lexariabioscience.com/news-events/press-releases/detail/229/lexarias-technology-improves-the-oral-performance-of-the

This Study is only meant to provide early-stage indicative information to Lexaria about the possibility of enhancing the pharmacokinetic ("PK") and pharmacodynamic performance of orally delivered GLP-1 drugs to assist in guiding the Lexaria team in additional investigations. This Study is not complete and additional results will be reported…

Yesterday, LEXX issued two PRs about animal studies, sending the stock up 33% today:

https://finance.yahoo.com/news/lexaria-begin-diabetes-weight-loss-140500945.html

Caveat emptor.

[biotech jim]

The LEXX website "Corporate Highlight Sheet" states a couple of ongoing studies evaluating their DehydraTECH methodology for semaglutide, and a comparison toRybelsus. AUC comparisons with their technology looks good.
Thx for posting on LEXX.